| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Ovary Syndrome | 58 | 2024 | 193 | 9.410 |
Why?
|
| Insulin Resistance | 32 | 2022 | 379 | 3.300 |
Why?
|
| Hyperandrogenism | 14 | 2022 | 38 | 2.640 |
Why?
|
| Diabetes Mellitus, Type 2 | 32 | 2022 | 1229 | 2.630 |
Why?
|
| Sleep Apnea, Obstructive | 10 | 2022 | 219 | 2.450 |
Why?
|
| Glucose Intolerance | 18 | 2022 | 100 | 1.990 |
Why?
|
| Metformin | 14 | 2022 | 125 | 1.540 |
Why?
|
| Insulin | 32 | 2022 | 1185 | 1.530 |
Why?
|
| Blood Glucose | 28 | 2022 | 867 | 1.520 |
Why?
|
| Androgens | 15 | 2018 | 162 | 1.410 |
Why?
|
| Hypoglycemic Agents | 19 | 2022 | 379 | 1.300 |
Why?
|
| Testosterone | 17 | 2015 | 259 | 1.130 |
Why?
|
| Ovary | 9 | 2016 | 254 | 0.980 |
Why?
|
| Glucose Tolerance Test | 23 | 2021 | 232 | 0.850 |
Why?
|
| Female | 90 | 2024 | 48702 | 0.690 |
Why?
|
| Ovarian Diseases | 6 | 2015 | 28 | 0.670 |
Why?
|
| Thiazolidinediones | 10 | 2007 | 77 | 0.660 |
Why?
|
| Metabolic Diseases | 2 | 2011 | 57 | 0.650 |
Why?
|
| Hirsutism | 10 | 2018 | 53 | 0.590 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 188 | 0.580 |
Why?
|
| Humans | 107 | 2024 | 93515 | 0.550 |
Why?
|
| Polymorphism, Genetic | 6 | 2005 | 826 | 0.530 |
Why?
|
| Adult | 60 | 2022 | 27918 | 0.530 |
Why?
|
| Dexamethasone | 10 | 2011 | 312 | 0.510 |
Why?
|
| Phosphoproteins | 3 | 2009 | 259 | 0.500 |
Why?
|
| Gonadotropin-Releasing Hormone | 9 | 2010 | 99 | 0.490 |
Why?
|
| Sleep | 4 | 2019 | 448 | 0.480 |
Why?
|
| Prediabetic State | 3 | 2021 | 42 | 0.480 |
Why?
|
| Chromans | 8 | 2005 | 28 | 0.460 |
Why?
|
| Hyperinsulinism | 5 | 2016 | 45 | 0.450 |
Why?
|
| Adrenocorticotropic Hormone | 6 | 2011 | 124 | 0.440 |
Why?
|
| Body Mass Index | 11 | 2013 | 811 | 0.440 |
Why?
|
| Obesity | 6 | 2019 | 1018 | 0.400 |
Why?
|
| Evidence-Based Medicine | 5 | 2024 | 449 | 0.390 |
Why?
|
| Islets of Langerhans | 6 | 2004 | 557 | 0.380 |
Why?
|
| Cardiovascular Diseases | 4 | 2021 | 754 | 0.370 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2012 | 11 | 0.370 |
Why?
|
| Depression | 2 | 2015 | 544 | 0.360 |
Why?
|
| Glucose | 7 | 2021 | 692 | 0.360 |
Why?
|
| Gastroplasty | 2 | 2022 | 27 | 0.350 |
Why?
|
| Metabolism | 1 | 2010 | 24 | 0.330 |
Why?
|
| Lipids | 3 | 2009 | 278 | 0.320 |
Why?
|
| Sleep Wake Disorders | 3 | 2019 | 124 | 0.320 |
Why?
|
| Hyperglycemia | 2 | 2017 | 181 | 0.300 |
Why?
|
| Nafarelin | 10 | 1996 | 32 | 0.300 |
Why?
|
| Adolescent | 26 | 2021 | 9606 | 0.300 |
Why?
|
| Diabetes Mellitus | 6 | 2018 | 767 | 0.300 |
Why?
|
| Thiazoles | 5 | 2003 | 124 | 0.280 |
Why?
|
| Insulin-Secreting Cells | 3 | 2019 | 441 | 0.280 |
Why?
|
| Leuprolide | 4 | 2010 | 34 | 0.270 |
Why?
|
| Exercise Therapy | 2 | 2019 | 94 | 0.270 |
Why?
|
| Metabolic Syndrome | 2 | 2005 | 122 | 0.250 |
Why?
|
| Androgen Antagonists | 4 | 2018 | 143 | 0.250 |
Why?
|
| Gonadotropins | 5 | 2010 | 33 | 0.230 |
Why?
|
| Genetic Variation | 3 | 2017 | 1415 | 0.230 |
Why?
|
| Young Adult | 14 | 2021 | 6930 | 0.230 |
Why?
|
| Polysomnography | 4 | 2012 | 153 | 0.220 |
Why?
|
| Respiratory Mechanics | 1 | 2005 | 108 | 0.220 |
Why?
|
| Case-Control Studies | 7 | 2018 | 1931 | 0.210 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2004 | 58 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2018 | 2465 | 0.210 |
Why?
|
| Mood Disorders | 1 | 2004 | 82 | 0.200 |
Why?
|
| Coronary Artery Disease | 2 | 2018 | 375 | 0.200 |
Why?
|
| Cohort Studies | 6 | 2019 | 3054 | 0.180 |
Why?
|
| Diabetes, Gestational | 2 | 2013 | 49 | 0.180 |
Why?
|
| Calpain | 1 | 2002 | 113 | 0.170 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 123 | 0.170 |
Why?
|
| Genome-Wide Association Study | 4 | 2018 | 1762 | 0.170 |
Why?
|
| Phenotype | 8 | 2018 | 2544 | 0.170 |
Why?
|
| Menstruation Disturbances | 2 | 2018 | 22 | 0.160 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 5 | 2011 | 24 | 0.160 |
Why?
|
| Sleep Deprivation | 2 | 2012 | 125 | 0.160 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 3830 | 0.160 |
Why?
|
| Hydroxyprogesterones | 4 | 1994 | 15 | 0.160 |
Why?
|
| Steroids | 3 | 2009 | 168 | 0.160 |
Why?
|
| Contraceptives, Oral | 2 | 2013 | 49 | 0.160 |
Why?
|
| Hypogonadism | 2 | 2010 | 43 | 0.150 |
Why?
|
| Pituitary Gland | 2 | 1989 | 116 | 0.150 |
Why?
|
| Luteinizing Hormone | 9 | 2009 | 149 | 0.150 |
Why?
|
| Oligomenorrhea | 4 | 2007 | 10 | 0.150 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 53 | 0.140 |
Why?
|
| Risk Reduction Behavior | 2 | 2017 | 99 | 0.140 |
Why?
|
| Time Factors | 8 | 2019 | 5410 | 0.140 |
Why?
|
| Thyroid Diseases | 2 | 1989 | 106 | 0.140 |
Why?
|
| Hair Removal | 1 | 2018 | 14 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2017 | 30 | 0.130 |
Why?
|
| Follicle Stimulating Hormone | 7 | 2009 | 135 | 0.130 |
Why?
|
| Weight Reduction Programs | 1 | 2017 | 12 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1053 | 0.130 |
Why?
|
| Thyrotropin | 2 | 1989 | 309 | 0.130 |
Why?
|
| Vascular Calcification | 1 | 2018 | 46 | 0.130 |
Why?
|
| Biomarkers | 3 | 2017 | 1910 | 0.130 |
Why?
|
| Fibrinolysis | 1 | 1997 | 36 | 0.130 |
Why?
|
| Glucocorticoids | 4 | 2004 | 362 | 0.130 |
Why?
|
| Middle Aged | 15 | 2021 | 27573 | 0.130 |
Why?
|
| Body Composition | 1 | 2017 | 74 | 0.130 |
Why?
|
| C-Peptide | 4 | 2019 | 184 | 0.130 |
Why?
|
| Acne Vulgaris | 3 | 2005 | 33 | 0.130 |
Why?
|
| Fasting | 3 | 2020 | 163 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2015 | 502 | 0.130 |
Why?
|
| Male | 24 | 2021 | 44557 | 0.130 |
Why?
|
| Self-Management | 1 | 2017 | 44 | 0.120 |
Why?
|
| Adrenal Glands | 3 | 2011 | 74 | 0.120 |
Why?
|
| Glucose Clamp Technique | 4 | 2019 | 42 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1997 | 152 | 0.120 |
Why?
|
| Hypoglycemia | 1 | 2017 | 113 | 0.120 |
Why?
|
| Reproduction | 1 | 2017 | 204 | 0.120 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 179 | 0.120 |
Why?
|
| Exercise | 1 | 2019 | 353 | 0.120 |
Why?
|
| Incidence | 3 | 2017 | 1701 | 0.120 |
Why?
|
| Amenorrhea | 2 | 2007 | 27 | 0.110 |
Why?
|
| Risk Factors | 8 | 2018 | 5899 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2011 | 579 | 0.110 |
Why?
|
| Surveys and Questionnaires | 5 | 2019 | 2802 | 0.110 |
Why?
|
| Hormones | 2 | 2010 | 136 | 0.110 |
Why?
|
| Adrenal Hyperplasia, Congenital | 2 | 1992 | 21 | 0.110 |
Why?
|
| Models, Biological | 2 | 2017 | 1768 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2017 | 237 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2011 | 4560 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2002 | 1691 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 373 | 0.100 |
Why?
|
| Research Design | 1 | 2017 | 617 | 0.100 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2004 | 56 | 0.100 |
Why?
|
| Area Under Curve | 2 | 2005 | 335 | 0.100 |
Why?
|
| Osmolar Concentration | 2 | 2012 | 168 | 0.100 |
Why?
|
| Diagnosis, Differential | 5 | 2005 | 1546 | 0.090 |
Why?
|
| Hyperlipidemias | 2 | 2003 | 91 | 0.090 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2012 | 5 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2015 | 342 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2017 | 1914 | 0.090 |
Why?
|
| Body Fat Distribution | 1 | 2011 | 13 | 0.090 |
Why?
|
| Dehydroepiandrosterone Sulfate | 3 | 2009 | 14 | 0.090 |
Why?
|
| Ovarian Function Tests | 2 | 2000 | 5 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1161 | 0.090 |
Why?
|
| Sex Characteristics | 3 | 2011 | 333 | 0.090 |
Why?
|
| Self Report | 3 | 2019 | 328 | 0.090 |
Why?
|
| Adipocytes | 1 | 2012 | 169 | 0.090 |
Why?
|
| Organ Size | 1 | 2012 | 362 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2004 | 392 | 0.090 |
Why?
|
| Age Factors | 2 | 2013 | 1906 | 0.080 |
Why?
|
| Disease Progression | 1 | 2015 | 1531 | 0.080 |
Why?
|
| Genotype | 4 | 2005 | 1866 | 0.080 |
Why?
|
| Animals | 7 | 2016 | 28155 | 0.080 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2010 | 11 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 1997 | 797 | 0.080 |
Why?
|
| Pituitary-Adrenal System | 1 | 2010 | 64 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2013 | 352 | 0.080 |
Why?
|
| Autonomic Nervous System | 1 | 2010 | 67 | 0.080 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2010 | 80 | 0.080 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2010 | 54 | 0.080 |
Why?
|
| Progesterone | 1 | 2010 | 112 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 589 | 0.080 |
Why?
|
| Child | 7 | 2021 | 7355 | 0.080 |
Why?
|
| Sympathetic Nervous System | 1 | 2010 | 99 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 1847 | 0.080 |
Why?
|
| Perilipin-1 | 1 | 2009 | 7 | 0.080 |
Why?
|
| Puberty, Delayed | 1 | 1989 | 18 | 0.080 |
Why?
|
| Homeostasis | 2 | 2002 | 460 | 0.080 |
Why?
|
| Pregnancy Outcome | 1 | 2011 | 268 | 0.080 |
Why?
|
| Pituitary Gland, Anterior | 1 | 1989 | 20 | 0.070 |
Why?
|
| Testis | 1 | 1989 | 148 | 0.070 |
Why?
|
| Estradiol | 4 | 2009 | 247 | 0.070 |
Why?
|
| Mutation, Missense | 2 | 2017 | 297 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2010 | 246 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2010 | 1713 | 0.070 |
Why?
|
| Electrocardiography | 1 | 2010 | 493 | 0.070 |
Why?
|
| Heart Rate | 1 | 2010 | 505 | 0.070 |
Why?
|
| Life Style | 3 | 2021 | 183 | 0.070 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 135 | 0.070 |
Why?
|
| Women's Health | 1 | 2009 | 107 | 0.070 |
Why?
|
| Sleep Stages | 1 | 2008 | 45 | 0.070 |
Why?
|
| Aged | 5 | 2019 | 20434 | 0.070 |
Why?
|
| Cholesterol, HDL | 2 | 2005 | 173 | 0.070 |
Why?
|
| Arousal | 1 | 2008 | 171 | 0.070 |
Why?
|
| Hemodynamics | 1 | 2010 | 713 | 0.060 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2007 | 18 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2009 | 663 | 0.060 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2005 | 11 | 0.060 |
Why?
|
| Waist-Hip Ratio | 1 | 2005 | 21 | 0.060 |
Why?
|
| Diet, Reducing | 1 | 2005 | 28 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 759 | 0.050 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2005 | 106 | 0.050 |
Why?
|
| AT Rich Sequence | 1 | 2004 | 6 | 0.050 |
Why?
|
| Alleles | 2 | 2012 | 1139 | 0.050 |
Why?
|
| Protein Phosphatase 1 | 1 | 2004 | 31 | 0.050 |
Why?
|
| Matched-Pair Analysis | 1 | 2003 | 40 | 0.050 |
Why?
|
| Mites | 1 | 2003 | 17 | 0.050 |
Why?
|
| Personality Inventory | 1 | 2004 | 111 | 0.050 |
Why?
|
| Premenopause | 2 | 2018 | 63 | 0.050 |
Why?
|
| Body Image | 1 | 2004 | 84 | 0.050 |
Why?
|
| Dust | 1 | 2003 | 26 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2004 | 225 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2002 | 657 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2017 | 2484 | 0.050 |
Why?
|
| Allergens | 1 | 2003 | 189 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 608 | 0.050 |
Why?
|
| Infertility, Female | 1 | 2003 | 98 | 0.050 |
Why?
|
| Receptor, Insulin | 1 | 2002 | 60 | 0.050 |
Why?
|
| Androstenedione | 2 | 1994 | 24 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 691 | 0.050 |
Why?
|
| Diabetic Angiopathies | 1 | 2002 | 37 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 1917 | 0.040 |
Why?
|
| DNA Primers | 1 | 2002 | 531 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2005 | 896 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 331 | 0.040 |
Why?
|
| 3-Hydroxysteroid Dehydrogenases | 2 | 1993 | 16 | 0.040 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2002 | 125 | 0.040 |
Why?
|
| Ovulation | 1 | 2001 | 66 | 0.040 |
Why?
|
| Ultrasonography | 3 | 2009 | 702 | 0.040 |
Why?
|
| Genetic Linkage | 2 | 1999 | 613 | 0.040 |
Why?
|
| Heterozygote | 1 | 2002 | 382 | 0.040 |
Why?
|
| Weight Loss | 1 | 2022 | 234 | 0.040 |
Why?
|
| Mutation | 1 | 2012 | 4272 | 0.040 |
Why?
|
| Haplotypes | 1 | 2002 | 647 | 0.040 |
Why?
|
| Receptors, LHRH | 1 | 1999 | 4 | 0.040 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 1999 | 32 | 0.040 |
Why?
|
| Jet Lag Syndrome | 1 | 2019 | 13 | 0.040 |
Why?
|
| Thrombosis | 1 | 2002 | 309 | 0.040 |
Why?
|
| Base Sequence | 1 | 2002 | 2220 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 1518 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 2012 | 0.030 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2018 | 8 | 0.030 |
Why?
|
| Glycoproteins | 1 | 1999 | 220 | 0.030 |
Why?
|
| Overweight | 1 | 2019 | 120 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 122 | 0.030 |
Why?
|
| Pregnancy | 3 | 2013 | 3147 | 0.030 |
Why?
|
| 17-alpha-Hydroxypregnenolone | 2 | 1994 | 8 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 1999 | 543 | 0.030 |
Why?
|
| Quality of Life | 2 | 2017 | 1780 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2017 | 34 | 0.030 |
Why?
|
| Preventive Health Services | 1 | 2018 | 38 | 0.030 |
Why?
|
| Glucokinase | 1 | 2017 | 61 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 1999 | 1052 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2017 | 80 | 0.030 |
Why?
|
| Postprandial Period | 1 | 2017 | 47 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1997 | 46 | 0.030 |
Why?
|
| Germany | 1 | 2017 | 81 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 1997 | 116 | 0.030 |
Why?
|
| Arginine | 1 | 2017 | 141 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1999 | 884 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2019 | 285 | 0.030 |
Why?
|
| Calcinosis | 1 | 2018 | 222 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 657 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 401 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 2495 | 0.030 |
Why?
|
| Liver | 1 | 2021 | 1210 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 829 | 0.030 |
Why?
|
| DNA | 1 | 2002 | 1265 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2001 | 701 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 159 | 0.030 |
Why?
|
| Hypertension | 1 | 2002 | 757 | 0.030 |
Why?
|
| Asthma | 1 | 2003 | 1039 | 0.030 |
Why?
|
| Virilism | 1 | 1994 | 5 | 0.030 |
Why?
|
| Adrenal Gland Diseases | 1 | 1994 | 10 | 0.030 |
Why?
|
| Neurosecretory Systems | 1 | 1994 | 35 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2017 | 439 | 0.030 |
Why?
|
| Prevalence | 1 | 1999 | 1321 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 170 | 0.030 |
Why?
|
| Dehydroepiandrosterone | 2 | 1993 | 45 | 0.030 |
Why?
|
| Self Care | 1 | 2015 | 167 | 0.030 |
Why?
|
| Chicago | 1 | 1999 | 1464 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 342 | 0.030 |
Why?
|
| Psychometrics | 1 | 2015 | 337 | 0.030 |
Why?
|
| Flutamide | 1 | 2013 | 3 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2017 | 556 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2013 | 69 | 0.020 |
Why?
|
| Societies, Scientific | 1 | 2013 | 41 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1723 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 1103 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 985 | 0.020 |
Why?
|
| Puberty | 1 | 1993 | 54 | 0.020 |
Why?
|
| Double-Blind Method | 3 | 2003 | 1729 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 557 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2012 | 75 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 390 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 630 | 0.020 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2011 | 71 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2017 | 9099 | 0.020 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 168 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 366 | 0.020 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 1 | 1990 | 7 | 0.020 |
Why?
|
| Dosage Forms | 1 | 2010 | 7 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2585 | 0.020 |
Why?
|
| Periodicity | 1 | 2010 | 113 | 0.020 |
Why?
|
| United States | 2 | 2015 | 7622 | 0.020 |
Why?
|
| Theca Cells | 1 | 2009 | 9 | 0.020 |
Why?
|
| Anovulation | 1 | 2009 | 10 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 1989 | 57 | 0.020 |
Why?
|
| Inhibins | 1 | 2009 | 32 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 2009 | 69 | 0.020 |
Why?
|
| Occupations | 1 | 2009 | 24 | 0.020 |
Why?
|
| Granulosa Cells | 1 | 2009 | 31 | 0.020 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2009 | 49 | 0.020 |
Why?
|
| 19-Iodocholesterol | 1 | 1988 | 1 | 0.020 |
Why?
|
| Adrenal Cortex Diseases | 1 | 1988 | 6 | 0.020 |
Why?
|
| Adrenal Cortex | 1 | 1988 | 20 | 0.020 |
Why?
|
| Cushing Syndrome | 1 | 1988 | 25 | 0.020 |
Why?
|
| Ovarian Follicle | 1 | 2009 | 66 | 0.020 |
Why?
|
| Immunoassay | 1 | 1989 | 99 | 0.020 |
Why?
|
| Hyperthyroidism | 1 | 1989 | 76 | 0.020 |
Why?
|
| Pelvis | 1 | 2009 | 100 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2009 | 89 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 1988 | 137 | 0.020 |
Why?
|
| Estrogens | 1 | 1989 | 195 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 2441 | 0.020 |
Why?
|
| Nuclear Family | 2 | 1999 | 92 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1243 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1985 | 0.020 |
Why?
|
| Pilot Projects | 1 | 1989 | 917 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 206 | 0.020 |
Why?
|
| Cholesterol | 1 | 1988 | 364 | 0.020 |
Why?
|
| Body Size | 1 | 2007 | 98 | 0.020 |
Why?
|
| Thyroid Hormones | 1 | 1989 | 350 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 1989 | 275 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 74 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2005 | 146 | 0.010 |
Why?
|
| Luciferases | 1 | 2005 | 129 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2005 | 275 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 889 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2009 | 438 | 0.010 |
Why?
|
| Bronchial Provocation Tests | 1 | 2003 | 24 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2003 | 23 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 880 | 0.010 |
Why?
|
| Aerosols | 1 | 2003 | 44 | 0.010 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2003 | 36 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 2003 | 111 | 0.010 |
Why?
|
| Histamine | 1 | 2003 | 116 | 0.010 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2003 | 64 | 0.010 |
Why?
|
| Immunization | 1 | 2003 | 154 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 155 | 0.010 |
Why?
|
| Immunoglobulin E | 1 | 2003 | 148 | 0.010 |
Why?
|
| Triglycerides | 1 | 2003 | 231 | 0.010 |
Why?
|
| Respiratory System | 1 | 2003 | 117 | 0.010 |
Why?
|
| Electroencephalography | 1 | 2008 | 797 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2003 | 149 | 0.010 |
Why?
|
| Prognosis | 1 | 2010 | 3911 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2003 | 246 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2012 | 3502 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2009 | 3829 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2003 | 464 | 0.010 |
Why?
|
| Adenosine | 1 | 2003 | 275 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2000 | 67 | 0.010 |
Why?
|
| Kinetics | 2 | 1993 | 1492 | 0.010 |
Why?
|
| Puberty, Precocious | 1 | 2000 | 31 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 863 | 0.010 |
Why?
|
| Minisatellite Repeats | 1 | 1999 | 23 | 0.010 |
Why?
|
| Follistatin | 1 | 1999 | 7 | 0.010 |
Why?
|
| Fathers | 1 | 1999 | 44 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1999 | 113 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1999 | 77 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1999 | 469 | 0.010 |
Why?
|
| Mothers | 1 | 1999 | 142 | 0.010 |
Why?
|
| Exons | 1 | 1999 | 450 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 1989 | 10164 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1997 | 163 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1999 | 894 | 0.010 |
Why?
|
| Lung | 1 | 2003 | 1366 | 0.010 |
Why?
|
| Information Systems | 1 | 1996 | 29 | 0.010 |
Why?
|
| Gene Expression | 1 | 2000 | 1301 | 0.010 |
Why?
|
| Japan | 1 | 1996 | 299 | 0.010 |
Why?
|
| Hydrolases | 1 | 1994 | 29 | 0.010 |
Why?
|
| Family | 1 | 1996 | 324 | 0.010 |
Why?
|
| Pedigree | 1 | 1996 | 961 | 0.010 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1994 | 83 | 0.010 |
Why?
|
| Models, Genetic | 1 | 1999 | 970 | 0.010 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 1988 | 21 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1988 | 242 | 0.000 |
Why?
|
| Hyperplasia | 1 | 1988 | 147 | 0.000 |
Why?
|
| Radionuclide Imaging | 1 | 1988 | 189 | 0.000 |
Why?
|
| Aging | 1 | 1993 | 727 | 0.000 |
Why?
|
| Mice | 1 | 2000 | 12269 | 0.000 |
Why?
|
| Adenoma | 1 | 1988 | 258 | 0.000 |
Why?
|
| Carcinoma | 1 | 1988 | 439 | 0.000 |
Why?
|